openPR Logo
Press release

Bronchitis Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Hanlim Pharm. Co., Ltd, Ahn-Gook Pharmaceuticals Co.,Ltd, PharmaKing, Johnson & Johnson

01-30-2025 07:26 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Bronchitis Market Predicted to See Upsurge Through 2032,

DelveInsight's "Bronchitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Bronchitis, historical and forecasted epidemiology as well as the Bronchitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Bronchitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bronchitis Market Forecast
https://www.delveinsight.com/sample-request/bronchitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Bronchitis Market Report:
• The Bronchitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In September 2024, CSA Medical, Inc. recently announced several presentations at the European Respiratory Society (ERS) Congress in Vienna, showcasing new clinical data supporting the use of Metered CryoSpray (MCS) with the RejuvenAir® System for treating Chronic Bronchitis. During the session titled "Cutting-edge concepts in interventional pulmonology: the future is here!", Dr. Christopher Orton, Consultant Respiratory Physician at Royal Brompton Hospital, London, presented research on the potential mechanisms behind bronchial epithelial resurfacing and remodeling using MCS for COPD patients with chronic bronchitis. The study confirmed the clinical effectiveness of Metered CryoSpray in alleviating chronic bronchitis symptoms, as well as a reduction in air trapping and signs of airway remodeling or "rejuvenation."
• In July 2024, CSA Medical finished enrolling participants in its SPRAY-CB trial (NCT03893370) for patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB). This double-blind, sham-controlled trial aims to assess the impact of the Boston-based company's RejuvenAir System on improving patient outcomes.
• In the 7MM, there were 19,517,000 cases of acute bronchitis in children and 29,174,000 cases in adults in 2022. During the predicted period, these cases are expected to rise
• Out of all the 7MM countries, Japan accounted for the least number of cases of chronic bronchitis, which formed ~4% of the total cases of chronic bronchitis in the 7MM
• In Germany, there were 1,574,000 cases of acute bronchitis in children and 2,819,000 cases in adults in 2022, respectively. During the predicted period, it is expected that these cases will rise
• In the 7MM in 2022, there were 26,954,000 cases of chronic bronchitis. By 2032, these cases are anticipated to rise
• In 2022, Germany reported the highest number of chronic bronchitis cases among the EU4 and the UK, accounting for approximately 54% of the total cases in the region.
• Key Bronchitis Companies: Hanlim Pharm. Co., Ltd, Ahn-Gook Pharmaceuticals Co.,Ltd, PharmaKing, Johnson & Johnson, Yuhan Corporation, Korea United Pharm. Inc., Hyundai Pharmaceutical Co., LTD., Ahn-Gook Pharma, Bayer, Wake Forest University, Pfizer, Sanofi, Pharmaxis, EmeraMed, Abgenix, and others
• Key Bronchitis Therapies: HL301, AGS, N02RS1, levofloxacin, YHD001, KALOMIN™, Acebrophylline, Synatura®, Avelox (Moxifloxacin, BAY12-8039), Oral N-acetycystein (NAC), Moxifloxacin, telithromycin, TPI 1020, Emeramide, ABX-IL8, and others
• The Bronchitis epidemiology based on gender analyzed that in most of the countries, male predominance was observed
• The Bronchitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bronchitis pipeline products will significantly revolutionize the Bronchitis market dynamics.

Bronchitis Overview
An inflammation of the airways entering the lungs is referred to as bronchitis. The person coughs as a result of the inflamed airways (trachea and bronchi) swelling and filling with mucus. The cough may linger a few days to a few weeks. The primary causes of bronchitis can include viruses, smoking, and other irritants.

Get a Free sample for the Bronchitis Market Report:
https://www.delveinsight.com/report-store/bronchitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bronchitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Bronchitis Epidemiology Segmentation:
The Bronchitis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Bronchitis
• Prevalent Cases of Bronchitis by severity
• Gender-specific Prevalence of Bronchitis
• Diagnosed Cases of Episodic and Chronic Bronchitis

Download the report to understand which factors are driving Bronchitis epidemiology trends @ Bronchitis Epidemiology Forecast
https://www.delveinsight.com/sample-request/bronchitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bronchitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bronchitis market or expected to get launched during the study period. The analysis covers Bronchitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Bronchitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Bronchitis Therapies and Key Companies
• HL301: Hanlim Pharm. Co., Ltd
• AGS: Ahn-Gook Pharmaceuticals Co.,Ltd
• N02RS1: PharmaKing
• levofloxacin: Johnson & Johnson
• YHD001: Yuhan Corporation
• KALOMIN™: Korea United Pharm. Inc.
• Acebrophylline: Hyundai Pharmaceutical Co., LTD.
• Synatura®: Ahn-Gook Pharma
• Avelox (Moxifloxacin, BAY12-8039): Bayer
• Oral N-acetycystein (NAC): Wake Forest University
• Moxifloxacin: Pfizer
• telithromycin: Sanofi
• TPI 1020: Pharmaxis
• Emeramide: EmeraMed
• ABX-IL8: Abgenix

Discover more about therapies set to grab major Bronchitis market share @ Bronchitis Treatment Market
https://www.delveinsight.com/sample-request/bronchitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Bronchitis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Bronchitis Companies: Hanlim Pharm. Co., Ltd, Ahn-Gook Pharmaceuticals Co.,Ltd, PharmaKing, Johnson & Johnson, Yuhan Corporation, Korea United Pharm. Inc., Hyundai Pharmaceutical Co., LTD., Ahn-Gook Pharma, Bayer, Wake Forest University, Pfizer, Sanofi, Pharmaxis, EmeraMed, Abgenix, and others
• Key Bronchitis Therapies: HL301, AGS, N02RS1, levofloxacin, YHD001, KALOMIN™, Acebrophylline, Synatura®, Avelox (Moxifloxacin, BAY12-8039), Oral N-acetycystein (NAC), Moxifloxacin, telithromycin, TPI 1020, Emeramide, ABX-IL8, and others
• Bronchitis Therapeutic Assessment: Bronchitis current marketed and Bronchitis emerging therapies
• Bronchitis Market Dynamics: Bronchitis market drivers and Bronchitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Bronchitis Unmet Needs, KOL's views, Analyst's views, Bronchitis Market Access and Reimbursement

To know more about Bronchitis companies working in the treatment market, visit @ Bronchitis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/bronchitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Bronchitis Market Report Introduction
2. Executive Summary for Bronchitis
3. SWOT analysis of Bronchitis
4. Bronchitis Patient Share (%) Overview at a Glance
5. Bronchitis Market Overview at a Glance
6. Bronchitis Disease Background and Overview
7. Bronchitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Bronchitis
9. Bronchitis Current Treatment and Medical Practices
10. Bronchitis Unmet Needs
11. Bronchitis Emerging Therapies
12. Bronchitis Market Outlook
13. Country-Wise Bronchitis Market Analysis (2019-2032)
14. Bronchitis Market Access and Reimbursement of Therapies
15. Bronchitis Market Drivers
16. Bronchitis Market Barriers
17. Bronchitis Appendix
18. Bronchitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports:
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bronchitis Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Hanlim Pharm. Co., Ltd, Ahn-Gook Pharmaceuticals Co.,Ltd, PharmaKing, Johnson & Johnson here

News-ID: 3842926 • Views:

More Releases from DelveInsight Business Research

Global Advanced Melanoma Pipeline Accelerates With 60+ Emerging Therapies, Reveals DelveInsight's 2025 Analysis
Global Advanced Melanoma Pipeline Accelerates With 60+ Emerging Therapies, Revea …
DelveInsight's "Advanced Melanoma Pipeline Insight 2025" report delivers an in-depth analysis of more than 55 companies and over 60 investigational therapies currently advancing through the Advanced Melanoma research landscape. It offers detailed profiles of both clinical- and preclinical-stage candidates and provides a thorough evaluation of therapies based on product type, development stage, route of administration, and molecule class. The report also outlines inactive or discontinued programs within this domain. Explore the
Global Spasticity Treatment Landscape Set for Transformation: DelveInsight Unveils Insights into 12+ Pipeline Therapies
Global Spasticity Treatment Landscape Set for Transformation: DelveInsight Unvei …
DelveInsight's "Spasticity Pipeline Insight, 2025" report offers an in-depth evaluation of 10+ companies and more than 12 investigational therapies currently advancing through the Spasticity treatment pipeline. The report includes detailed profiles of clinical- and preclinical-stage candidates, along with a thorough assessment of therapies by product type, development phase, route of administration, and molecular class. It also highlights discontinued and inactive programs in the field. Stay informed with the latest developments! Access
Lewy Body Dementia Treatment Market 2034 - Market Size, Competitive Landscape, Clinical Trials, Market Dynamics, Epidemiology, Companies | DelveInsight
Lewy Body Dementia Treatment Market 2034 - Market Size, Competitive Landscape, C …
The Lewy Body Dementia (LBD) market across the seven major markets (7MM) was valued at approximately USD 670 million in 2022, with strong growth anticipated through 2034. In 2022, an estimated 11 million dementia cases were recorded across the 7MM, of which ~0.6 million were attributed to Lewy Body Dementia. Rising disease prevalence-driven by aging demographics, enhanced diagnostic capabilities, and increasing awareness-is expected to stimulate market expansion. Companies including EIP
Bronchitis Treatment Market 2034: Market Size, Competitive Landscape, Companies, Clinical Trials, FDA Aprrovasls and Future Outlook by DelveInsight
Bronchitis Treatment Market 2034: Market Size, Competitive Landscape, Companies, …
The bronchitis therapeutics market is projected to grow steadily from 2025-2034, driven by rising disease prevalence, technological progress, and the emergence of new treatment options. Current management focuses on symptom relief through bronchodilators, corticosteroids, and antibiotics for acute cases, while chronic bronchitis requires long-term inhaled therapies, pulmonary rehabilitation, and lifestyle changes. A key advancement is the FDA-approved OHTUVAYRE (ensifentrine), which offers dual bronchodilator and anti-inflammatory benefits. Despite progress, there is

All 5 Releases


More Releases for Bronchitis

Rising Respiratory Disease Incidence Sparks Robust Growth In Bronchitis Treatmen …
The Bronchitis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Projected Growth of the Bronchitis Treatment Market? The market for bronchitis treatments has seen robust expansion in the past few years, with projections showing an increase from $5.61 billion in 2024 to
Acute Bronchitis Treatment Market: An In-Depth Analysis
The global Acute Bronchitis Treatment market was valued at approximately USD 6.3 billion in 2023 and is projected to reach around USD 9.9 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 5.3% during the forecast period. Acute Bronchitis Treatment Market Overview Acute bronchitis is a common respiratory condition characterized by inflammation of the bronchial tubes, leading to symptoms such as coughing and mucus production. The market's growth
Bronchitis Treatment Market Statistical Forecast, Trade Analysis 2024 - 2031
DataM Intelligence has published a new research report on "Bronchitis Treatment Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status. Get a Free Sample Research PDF -
Bronchitis Treatment Market Outlook, Insights, Size 2024-2033
The bronchitis treatment market size has grown strongly in recent years. It will grow from $5.25 billion in 2023 to $5.58 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising air pollution levels, cigarette smoking epidemic, increased respiratory infections, environmental and occupational exposures, lifestyle factors.. The bronchitis treatment market size is expected to see strong
Acute Bronchitis Treatment Market: What are the key opportunities?
The report attempts to offer high-quality and accurate analysis of the global Acute Bronchitis Treatment Market, keeping in view market forecasts, competitive intelligence, and technological risks and advancements, and other important subjects. Its carefully crafted market intelligence allows market participants to understand the most significant developments in the global Acute Bronchitis Treatment market that are impacting their business. Readers can become aware of crucial opportunities available in the global Acute
Bronchitis Market: Study Navigating the Future Growth Outlook
Global Bronchitis Market Report 2019 - Market Size, Share, Price, Trend and Forecast is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Bronchitis Market. Some of the key players profiled in the study are